For localized information and support, would you like to switch to your country-specific website for {0}?
Key takeaways
- Strong global presence at ESC: Presented our comprehensive range of Roche Diagnostics solutions for Cardiovascular, Renal, and Metabolism (CVRM), including testing options and platforms to help identify patients earlier, Ahead of care, who may be at risk for a cascade of interconnected diseases
- We had meetings throughout the duration of the congress about future pipeline projects, proposed clinical studies, and areas where ongoing collaboration and partnership will help accelerate medical value
- The Roche booth provided an opportunity for impromptu meetings and interactive presentations across a range of topics, including healthcare consulting, Strong-HF, LumiraDx, ACS, heart failure and cobas sense (still in development, not available commercially)
- More than 33,800 attendees gathered across a range of subspecialties, resulting in a strong scientific presence to discuss new evidence, the value of cardiac biomarkers, the utility of AI and to further drive the development of guidelines and real-world ideas to help improve patient management and outcomes
Ahead of care
At Roche, we have made it our mission to lead a paradigm shift: moving care from fragmented, late-stage interventions to proactive, integrated, and continuous disease management that puts us ahead of care. We are doing this by building interconnected "Solution Ecosystems" that combine AI-enabled digital algorithms, point-of-care decentralized testing and highly accurate lab tests.
We aim to deliver holistic care for people living with cardiometabolic conditions - from diagnosis to treatment to on-going monitoring. Our goal is to enable excellence in patient-centric decision-making and help tackle the high burden of Cardiometabolic diseases in our society.
Ahead of interconnected diseases
Cardiometabolic diseases are an ever-growing public health emergency. Their risks are also often interconnected, making earlier testing and intervention all the more important. We connected with peers and experts, explored our latest innovations, and experienced how Roche is at the forefront of cardiometabolic disease management.
We are dedicated to continuous research and development to target your biggest concerns. Explore how our technologies and comprehensive diagnostic solutions can help you act early, decide with confidence, and rely on solutions with built with the future in mind.
Watch our short video below to learn more.
Ahead of care
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
Show video transcript
Highlights of the booth
This event was a premier opportunity to explore the forefront of medical innovation. The immersive experience at our booth inspired you to learn about:
- Advancing Cardiovascular, Renal, and Metabolism (CVRM) drug development
- Engaging in clinical dialogue with scientific leaders
- Our cardiometabolic portfolio: At the forefront of disease management
- The Roche ACS Ecosystem - Our latest innovations: Elecsys® Troponin T hs Gen 6, setting a new benchmark for high-sensitivity testing, and the upcoming cobas® sense platform*—aiming to bring lab-like performance right to the point of care with results fully standardized to our core lab assay.
- Cardiovascular Risk Ecosystem - Our Lp(a)1 and hsCRP2 assays empower clinicians by providing the actionable data necessary for targeted cardiovascular risk stratification.
- Heart Failure Ecosystem - We support clinical decision making at every stage of care in heart failure, with assays that can help provide diagnostic confidence. Empowering heart failure decisions with diagnostic solutions tailored for diverse clinical settings.
- Advancing CV Therapeutics - The Roche Pharma CV pipeline, focused on addressing the most pressing unmet needs in cardiovascular care: learn more.
*cobas® sense is in development, not approved by regulatory bodies, and not commercially available. Intended product specifications, information and timelines are design goals and might be subject to change.
References
1. F. Hoffmann-La Roche Ltd. LPA2 Tina-quant Lipoprotein (a) Gen.2 Method Sheet. (v6.0). 2024.
2. F. Hoffmann-La Roche Ltd. HSCRP Tina-quant Cardiac high sensitivity CRP III Method Sheet. (v1.0). 2025.